Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmunotherapy regimens. More recently, small molecule inhibitors targeting kinases involved in a number of critical signaling pathways and a small molecule inhibitor of the BCL-2 family of proteins have demonstrated activity for the treatment of patients with CLL/SLL. These NCCN Guidelines Insights highlight important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/ SLL for the treatment of patients with newly diagnosed or relapsed/refractory CLL/SLL.
|Original language||English (US)|
|Number of pages||19|
|Journal||JNCCN Journal of the National Comprehensive Cancer Network|
|State||Published - Mar 1 2017|
ASJC Scopus subject areas